Common mechanisms for the regulation of B cell differentiation and transformation by the transcriptional repressor protein BCL-6

Immunologic Research

Volumn 37, Issue 3, 2007, Pages 177-186

  Kusam, Saritha ^b   Dent, Alexander ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

B cell; BCL 6; bcl6; Differentiation; Germinal center; Immortalization; Non Hodgkin's lymphoma; Plasma cell; Telomerase

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD69 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HERMES ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; PROTEIN BCL 6; PROTEIN BCL XL; PROTEIN P53; STAT1 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE;

B LYMPHOCYTE ACTIVATION; CANCER CELL CULTURE; CELL DEATH; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CHROMOSOME TRANSLOCATION; FOLLICULAR DENDRITIC CELL; GENE OVEREXPRESSION; GERMINAL CENTER; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IMMUNOSTIMULATION; KNOCKOUT MOUSE; MALIGNANT TRANSFORMATION; MUTATIONAL ANALYSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SENESCENCE; TRANSCRIPTION TERMINATION; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; HUMANS; LYMPHOMA; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-BCL-6; SIGNAL TRANSDUCTION; TELOMERASE;

EID: 35348821203     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02697368     Document Type: Review

References (46)

1. Onizuka T, Moriyama M, Yamochi T, et al: BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts. Blood 1995; 86(1): 28-37.
2. Cattoretti G, Chang CC, Cechova K, et al: BCL-6 protein is expressed in germinal-center B cells. Blood 1995; 86(1): 4-53.
3. MacLennan IC: Germinal centers. Annu Rev Immunol 1994; 12: 117-139.
4. Ozaki K, Spolski R, Ettinger R, et al: Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp- 1 and Bcl-6. J Immunol 2004; 173(9): 5361-5371.
5. Arguni E, Arima M, Tsuruoka N, et al: JunD/AP-1 and STAT3 are the major enhancer molecules for high Bcl-6 expression in germinal center B cells. Int Immunol 2006; 18(7): 1079-1089.
6. Allman D, Jain A, Dent A, et al: BCL-6 expression during B-cell activation. Blood 1996; 87(12): 5257-5268.
7. Lee SC, Bottaro A, Chert L, Insel RA: Mad1 is a transcriptional repressor of Bcl-6. Mol Immunol 2006; 43(12): 1965-1971.
8. Calame KL, Lin KI, Tunyaplin C: Regulatory mechanisms that determine the development and function of plasma cells. Annu Rev Immunol 2003; 21: 205-230.
9. Pasqualucci L, MigliazzaA, Basso K, et al: Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 2003; 101: 2914-2923.
10. Wang X, Li Z, Naganuma A, Ye BH: Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. Proc Natl Acad Sci USA 2002; 99(23): 15018-15023.
11. Fujita N, Jaye DL, Geigerman C, et al: MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell 2004; 119(1): 75-86.
12. Fukuda T, Yoshida T, Okada S, et al: Disruption of the Bcl6 gene results in an impaired germinal center formation. J Exp Med 1997; 186(3): 439-448.
13. Toney LM, Cattoretti G, Graf JA, et al: BCL-6 regulates chemokine gene transcription in macrophages. Nat Immunol 2000; 1(3): 214-220.
14. Staudt LM, Dent AL, Shaffer AL, Yu X: Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6. Int Rev Immunol 1999; 18(4): 381-403.
15. Ye BH, Lista F, Lo Coco F, et al: Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large- cell lymphoma. Science 1993; 262(5134): 747-750.
16. Ye BH, Chaganti S, Chang CC, et al: Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J 1995; 14(24): 6209-6217.
17. Niu H: The proto-oncogene BCL-6 in normal and malignant B cell development. Hematol Oncol 2002; 20(4): 155-166.
18. Dent AL, Vasanwala FH, Toney LM: Regulation of gene expression by the proto-oncogene BCL-6. Crit Rev Oncol Hematol 2002; 41(1): 1-9.
19. Shaffer AL, Yu X, He Y, et al: BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000; 13(2): 199-212.
20. Phan RT, Saito M, Basso K, et al: BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol 2005; 6(10): 1054-1060.
21. Reljic R, Wagner SD, Pealanan LJ, Fearon DT: Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6. J Exp Med 2000; 192(12): 1841-1848.
22. Shaffer AL, Lin KI, Kuo TC, et al: Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002; 17(1): 51-62.
23. Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, et al: Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 2003; 19(4): 607-620.
24. Baron BW, Anastasi J, Thimlan MJ, et al: The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis. Proc Natl Acad Sci USA 2002; 99(5): 2860-2865.
25. Phan RT, Dalla-Favera R: The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004; 432(7017): 635-639.
26. Kusam S, Vasanwala FH, Dent AL: Transcriptional repressor BCL-6 immortalizes germinal center-like B cells in the absence of p53 function. Oncogene 2004; 23(3): 839-844.
27. Miles RR, Crockett DK, Lim MS, Elenitoba-Johnson KS: Analysis of BCL6-interacting proteins by tandem mass spectrometry. Mol Cell Proteomics 2005; 4(12): 1898-1909.
28. Vasanwala FH, Kusam S, Toney LM, Dent AL: Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J Immunol 2002; 169(4): 1922-1929.
29. Huynh KD, Bardwell VJ: The BCL-6 POZ domain and other POZ domains interact with the co-repressors NCoR and SMRT. Oncogene 1998; 17(19): 2473-2484.
30. Huynh KD, Fisclile W, Verdin E, Bardwell VJ: BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev 2000; 14(14): 1810-1823.
31. Ohkubo Y, Arima M, Arguni E, et al: A role for c-fos/ activator protein 1 in B lymphocyte terminal differentiation. J Immunol 2005; 174(12): 7703-7710.
32. Dent AL, Shaffer AL, Yu X, et al: Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 1997; 276(5312): 589-592.
33. Ye BH, Cattoretti G, Shen Q, et al: The BCL-6 protooncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet 1997; 16(2): 161-170.
34. Tunyaplin C, Shaffer AL, Angelin-Duclos CD, et al: Direct repression of prdml by Bcl-6 inhibits plasmacytic differentiation. J Immunol 2004; 173(2): 1158-1165.
35. Baron BW, Anastasi J, Montag A, et al: The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci USA 2004; 101(39): 14198-14203.
36. Cattoretti G, Pasqualucci L, Ballon G, et al: Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 2005; 7(5): 445-455.
37. Polo JM, Dell'Oso T, Ranuncolo SM, et al: Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 2004; 10(12): 1329-1335.
38. Clodi K, Asgary Z, Zhao S, et al: Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol 1998; 103(1): 270-275.
39. Pham LV, Tamayo AT, Yoshimura LC, et al: A CD40 signalosome anchored in lipid rafts leads to constitutive ac tivation of NF-kappaB and autonomous cell growth in B cell lymphomas. Immunity 2002; 16(1): 37-50.
40. Pham LV, Tamayo AT, Yoshimura LC, et al: Constitutive NF-{kappa}B and NFAT activation in aggressive B cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood 2005; 106(12); 3940-3947.
41. Sharpless NE, DePinho RA: Telomeres, stem cells, senescence, and cancer. J Clin Invest 2004; 113(2): 160-168.
42. Klingelhutz AJ: The roles of telomeres and telomerase in cellular immortalization and the development of cancer. Anticancer Res 1999; 19(6A): 4823-4830.
43. Hu BT, Insel RA: Up-regulation of telomerase in human B lymphocytes occurs independently of cellular proliferation and with expression of the telomerase catalytic subunit. Eur J Immunol 1999; 29(11): 3745-3753.
44. Norrback KF, Dahlenborg K, Carlsson R, Roos G: Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas. Blood 1996; 88(1): 222-229.
45. Hodes RJ, Hathcock KS, Weng NP: Telomeres in T and B cells. Nat Rev Immunol 2002; 2(9): 699-706.
46. Hu BT, Lee SC, Main E, et al: Telomerase is up-regulated in human germinal center B cells in vivo and can be re-expressed in memory B cells activated in vitro. J Immunol 1997; 159(3): 1068-1071.